• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting 2025

November 6 - 10, 2025

  1. FASENRA (benralizumab)
  2. TEZSPIRE (tezepelumab)
  3. AIRSUPRA (albuterol/budesonide)
  4. Respiratory Unbranded

PDF

Model-based comparison of eosinophilic depletion following treatment with benralizumab, depemokimab and mepolizumab

PDF

CROSSROADS-3: Real-world reduction of exacerbations, healthcare utilization and corticosteroid use with tezepelumab in severe asthma

PDF

Reduction in exacerbations increased over time in US real-world severe asthma patients initiating tezepelumab: CROSSROADS-4

PDF

Tezepelumab efficacy in patients with severe, uncontrolled asthma by exacerbation triggers in NAVIGATOR and DIRECTION

PDF

Efficacy of biologics in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps

PDF

Clinical outcomes after tezepelumab cessation following 52 weeks of treatment in adults with severe CRSwNP

PDF

Sense of smell improvements with tezepelumab in patients with chronic rhinosinusitis with nasal aolyps (WAYPOINT)

PDF

Tezepelumab treatment improves rhinosinusitis symptoms and HRQoL across SNOT-22 domains in adults with severe CRSwNP

HTML

Tezepelumab in Allergic Rhinitis and asthma Study (TEZARS): Improvement in nasal symptoms 6-months post-treatment

PDF

Real-World impact of tezepelumab on exacerbations, healthcare utilization, and costs among US patients (CROSSROADS-1)

PDF

Combination short-acting bronchodilator and inhaled corticosteroid rescue therapy (the ANCHOR Study): rationale and design

PDF

Albuterol-budesonide treatment in acute airway obstruction: onset and duration of lung function and symptom improvement

PDF

Use of as-needed albuterol-budesonide versus albuterol before and after a severe exacerbation: BATURA post-hoc analysis

PDF

Patient characteristics from MT RAINIER: asthma quality improvement program across multi-site allergy community practices

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States (Take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2025 AstraZeneca. All rights reserved.

US-69609; US-91816; US-103094; US-106788

Last Updated 11/25

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Consumer Health Data Privacy Notice

Privacy Notice

Legal Notice

Cookie Preferences

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Survey Feedback

Your Privacy Choices

Consumer Health Data Privacy Notice

Pharma Logo

Privacy NoticeLegal NoticeCookie Preferences